Randomized, Double-Blind Phase 2b Data in 327 Patients, Plus New Mechanistic Research, to Be Presented October 23 in Denver Kibow Therapeutics, a clinical-stage biotechnology company advancing microbiome-based therapies for chronic…
Read More
Randomized, Double-Blind Phase 2b Data in 327 Patients, Plus New Mechanistic Research, to Be Presented October 23 in Denver Kibow Therapeutics, a clinical-stage biotechnology company advancing microbiome-based therapies for chronic…
Kibow Therapeutics is a development stage company that markets no products at this time. The product candidates on this website have not been approved by any regulatory body.